Document Classification

Section Type: METHODS

Text: Participants were randomly assigned by web-based permuted block randomisation (block size 4) in a 1:1:1:1 ratio to the four treatment groups : cisplatin (50 mg/m (2) intravenously on day 1 or 2 of the treatment cycle) and paclitaxel (135 mg/m (2) intravenously over 24 h or 175 mg/m (2) intravenously over 3 h on day 1), with or without bevacizumab (15 mg/kg intravenously on day 1 or 2), or paclitaxel (175 mg/m (2) over 3 h on day 1) and topotecan (075 mg/m (2) for 30 min on days 1-3) with or without bevacizumab (15 mg/kg intravenously on day 1).